• Miscellaneous immune disorders

Rezurock Generic Name & Formulations

General Description

Belumosudil 200mg; tabs.

Pharmacological Class

Kinase inhibitor.

How Supplied


Generic Availability


Rezurock Indications


Chronic graft-versus-host disease (GVHD) after failure of ≥2 prior lines of systemic therapy.

Rezurock Dosage and Administration


Swallow whole. Take with food at the same time each day. 200mg once daily until progression of chronic GVHD that requires new systemic therapy. Concomitant strong CYP3A inducers, PPIs: increase to 200mg twice daily.


<12yrs: not established.

Rezurock Contraindications

Not Applicable

Rezurock Boxed Warnings

Not Applicable

Rezurock Warnings/Precautions


Monitor LFTs (total bilirubin, AST, ALT) at least monthly. Discontinue permanently if Grade 4 AST/ALT (>20×ULN), Grade ≥3 bilirubin (>3×ULN), or other Grade 4 adverse reactions occur. Withhold if Grade 3 AST/ALT (5–20×ULN), Grade 2 bilirubin (1.5–3×ULN), or other Grade 3 adverse reactions occur until recovery to Grade 0–1; then resume treatment. Pre-existing severe renal or hepatic impairment: not studied. Embryo-fetal toxicity. Advise females of reproductive potential and males (w. female partners) to use effective contraception during and for ≥1 week after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for ≥1 week after the last dose).

Rezurock Pharmacokinetics

See Literature

Rezurock Interactions


Antagonized by strong CYP3A inducers (eg, rifampin), PPIs (eg, rabeprazole, omeprazole); increase dose (see Adult).

Rezurock Adverse Reactions

Adverse Reactions

Infections, asthenia, nausea, diarrhea, dyspnea, cough, edema, hemorrhage, abdominal pain, musculoskeletal pain, headache, decreased phosphate, decreased lymphocytes, increased GGT, hypertension; hepatotoxicity.

Rezurock Clinical Trials

See Literature

Rezurock Note

Not Applicable

Rezurock Patient Counseling

See Literature